4881.T stock led Japan’s small-cap gainers at market close on 17 Mar 2026, rising 19.61% to JPY 122.00 on the JPX. The move came on heavy turnover of 5,624,300.00 shares versus an average of 1,770,821.00, a relative volume of 3.64. Investors priced in clinical-stage updates and short-covering after a fresh run above the 50-day average of JPY 91.40. We examine the drivers behind today’s jump, the financial profile, technical signals, Meyka AI grade and a forecast comparison to highlight where risk and opportunity sit for FunPep Company Limited (4881.T)
Intraday move and trading context for 4881.T stock
FunPep (4881.T) closed at JPY 122.00, up 20.00 points or 19.61% on the session. The stock hit a day high of JPY 124.00 and a day low of JPY 108.00. Volume spiked to 5,624,300.00 shares, well above the 50-day average of 1,770,821.00, suggesting conviction among traders. The market cap stood at JPY 4,664,835,620.00, with 40,563,788.00 shares outstanding, indicating outsized moves can follow news in this float size.
Clinical catalysts and news drivers behind the jump in 4881.T stock
FunPep is a biotech listed on the JPX developing peptide therapeutics, including Phase II assets such as FPP003. Today’s rally appears tied to renewed market attention on Phase II timelines and potential trial-readout windows. The company’s website and filings remain key sources for formal updates; investors should watch the next clinical milestone before extrapolating gains. For the company site see FunPep site and company listing details at JPX.
Valuation and financials: why 4881.T stock still shows wide gaps
FunPep shows a high cash buffer and stretched operating metrics. Cash per share is JPY 44.54, book value per share is JPY 36.88, and current ratio is 3.74, which supports near-term funding needs. Revenue per share is JPY 0.01 and EPS is -42.10, producing a negative PE of -2.73. Price-to-book at 3.12 and price-to-sales near 14,856.16 reflect limited sales versus development spending. These ratios explain why today’s pop sits on speculation rather than improved earnings.
Technical outlook and trading signals for 4881.T stock
Momentum and volume indicators favor bulls currently. RSI is 62.48, MACD histogram is 0.95, and ADX reads 33.45 indicating a strong trend. Bollinger middle band sits near JPY 98.45 and the 50-day average is JPY 91.40. Near-term resistance is the year high at JPY 127.00 and support sits around JPY 100.28 (200-day average). Traders may use intraday ATR of 9.63 to size risk.
Meyka AI grade and model forecast for 4881.T stock
Meyka AI rates 4881.T with a score out of 100. Meyka AI rates 4881.T with a score out of 100: 67.29 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 50.53, a monthly median near JPY 67.31, and a quarterly level at JPY 57.17. Relative to the current price JPY 122.00, the yearly model implies an estimated downside of -58.56%. Forecasts are model-based projections and not guarantees.
Risks and near-term opportunities for 4881.T stock
The biggest upside is a positive clinical readout or partner deal that materially improves revenue prospects. Key risks include negative trial results, continued net losses, and valuation compression given negligible sales. FunPep’s EPS of -42.10 and heavy R&D to revenue ratio spotlight execution risk. Near-term opportunity windows align with clinical updates and large-volume breakouts above JPY 127.00.
Final Thoughts
FunPep (4881.T) led today’s small-cap gainers on the JPX, closing 19.61% higher at JPY 122.00 on 17 Mar 2026 amid heavy volume (5,624,300.00) and clinical-stage interest. The stock’s technical picture is constructive, with RSI 62.48 and a clear trend, but fundamentals remain mixed: strong cash per share (JPY 44.54) and a high current ratio (3.74) offset by negative EPS (-42.10) and very high price-to-sales. Meyka AI assigns a B (67.29) grade and a yearly model projection of JPY 50.53, implying a model-based downside of -58.56% versus today’s close. Active traders may chase momentum into clear catalysts. Long-term investors should wait for clinical proof points or partnership announcements before increasing exposure. For quick reference and filings, see the company site and JPX listing, and view our detailed stock page at Meyka 4881.T. Meyka AI provides this as data-driven market analysis, not individualized advice.
FAQs
What drove the 19.61% rise in 4881.T stock today?
The jump in 4881.T stock on 17 Mar 2026 was driven by heavy volume and renewed focus on Phase II clinical catalysts. Short-covering and a move above the 50-day average also supported buying. Check company releases for formal trial updates.
How does Meyka AI view 4881.T stock from a risk-reward lens?
Meyka AI grades 4881.T a B (67.29) with a HOLD bias. The model highlights high cash per share but negative EPS and trial risk. A positive clinical readout is the main upside catalyst; failed results would likely compress value.
What is the Meyka AI price forecast and implied change for 4881.T stock?
Meyka AI’s yearly forecast for 4881.T stock is JPY 50.53, versus a current close of JPY 122.00, implying a model-based downside of -58.56%. Forecasts are model projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)